Literature DB >> 8854584

Drug related involvement of specific sites in fixed eruptions: a statistical evaluation.

V K Sharma1, S Dhar, A N Gill.   

Abstract

Different drugs produce fixed eruptions over different parts of the body. However, the significance of preferential site involvement in fixed eruptions due to specific drugs has not been statistically evaluated. One hundred and twenty five patients of fixed drug eruption (FDE) were studied to examine this question. Different sites affected by individual drugs were classified as lips alone, genitalia alone, lips and genitalia together, trunk alone, trunk and limbs together, and generalized. Statistical analysis was carried out for 7 common drugs causing FDE in 5 or more patients. Cotrimoxazole, a combination of sulfamethoxazole and trimethoprim, was the most common offender for FDE (32.8%), followed by analgin (12%), tetracycline (8%), pyrazolones (8%), metronidazole (6.4%), ciprofloxacin (5.6%), and phenytoin sodium (4%). Major sites involved by FDE were trunk and limbs (24%), lips alone (20.8%), genitalia alone (20%), generalised (14.4%), lips and genitalia together (11.2%), and trunk alone (8.8%). Seventy-two (57.6%) patients had multiple lesions; 33 (42.4%) had single lesions. Involvement of mucocutaneous junctions of lips and genitalia by FDE was frequently caused by cotrimoxazole and tetracycline; trunk and limbs, by analgin and pyrazolones. Generalised eruptions were commonly caused by cotrimoxazole and phenytoin. The present statistical analysis confirms the clinical impression that genitalia alone are frequently involved in FDE due to tetracyclines (p < 0.001). FDE over trunk and limbs was significantly associated with analgin (p < 0.001), and generalised eruptions, with phenytoin sodium (p < 0.001). The association of FDE over lips with cotrimoxazole was statistically not significant.

Entities:  

Mesh:

Year:  1996        PMID: 8854584     DOI: 10.1111/j.1346-8138.1996.tb02646.x

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  9 in total

1.  Maximal Points of Head's Zone in Fixed Drug Eruption.

Authors:  Sang Sin Lee; Dong Kyun Hong; Myung Im; Young Lee; Young Joon Seo; Jeung Hoon Lee
Journal:  Ann Dermatol       Date:  2011-12-27       Impact factor: 1.444

Review 2.  [Allergic diseases in the genital area].

Authors:  J Eubel; T L Diepgen; E Weisshaar
Journal:  Hautarzt       Date:  2015-01       Impact factor: 0.751

3.  Mucosal fixed drug eruption in a patient treated with ornidazole.

Authors:  Charu Mohan Marya; Gaurav Sharma; Vijay P Parashar; Vandana Dahiya
Journal:  J Dermatol Case Rep       Date:  2012-03-27

4.  Fixed drug eruption resulting from fluconazole use: a case report.

Authors:  Mahkam Tavallaee; Mahnaz Mahmoudi Rad
Journal:  J Med Case Rep       Date:  2009-07-06

5.  Multifocal Bullous Fixed Drug Erruption Due To Phenytoin: A Lesson Learned!

Authors:  Ankur Jain; Naresh Gupta
Journal:  J Clin Diagn Res       Date:  2015-12-01

Review 6.  Oral pigmented lesions: Clinicopathologic features and review of the literature.

Authors:  Rogério-Oliveira Gondak; Rogério da Silva-Jorge; Jacks Jorge; Márcio-Ajudarte Lopes; Pablo-Agustin Vargas
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2012-11-01

7.  Mild cutaneous reactions to drugs.

Authors:  Giuseppe Crisafulli; Fabrizio Franceschini; Silvia Caimmi; Paolo Bottau; Lucia Liotti; Francesca Saretta; Roberto Bernardini; Fabio Cardinale; Francesca Mori; Carlo Caffarelli
Journal:  Acta Biomed       Date:  2019-01-28

8.  Fixed drug eruption due to clarithromycin.

Authors:  Santoshi Balkrishna Malkarnekar; L Naveen
Journal:  J Res Pharm Pract       Date:  2013-10

9.  Clinical features of fixed drug eruption at a tertiary hospital in Korea.

Authors:  Jae-Woo Jung; Sang-Heon Cho; Kyu-Han Kim; Kyung-Up Min; Hye-Ryun Kang
Journal:  Allergy Asthma Immunol Res       Date:  2014-03-26       Impact factor: 5.764

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.